Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Change in Account Payables (2016 - 2025)

Wave Life Sciences (WVE) has disclosed Change in Account Payables for 11 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Account Payables fell 66.59% year-over-year to $1.2 million, compared with a TTM value of -$561000.0 through Dec 2025, down 116.4%, and an annual FY2025 reading of -$561000.0, down 116.4% over the prior year.
  • Change in Account Payables was $1.2 million for Q4 2025 at Wave Life Sciences, up from $59000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $6.1 million in Q2 2024 and bottomed at -$5.1 million in Q3 2024.
  • Average Change in Account Payables over 5 years is $94000.0, with a median of $205000.0 recorded in 2023.
  • Peak annual rise in Change in Account Payables hit 2701.38% in 2024, while the deepest fall reached 1109.54% in 2024.
  • Year by year, Change in Account Payables stood at -$232000.0 in 2021, then surged by 535.78% to $1.0 million in 2022, then plummeted by 81.01% to $192000.0 in 2023, then soared by 1702.08% to $3.5 million in 2024, then plummeted by 66.59% to $1.2 million in 2025.
  • Business Quant data shows Change in Account Payables for WVE at $1.2 million in Q4 2025, $59000.0 in Q3 2025, and $276000.0 in Q2 2025.